Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies I: CT and MRI01:14

Imaging Studies I: CT and MRI

1.0K
Introduction: MRI and CT scans are crucial advancements in medical imaging techniques, playing a vital role in diagnosing conditions related to the gastrointestinal (GI) system. Each scan serves distinct purposes, targets specific areas, and requires unique nursing duties.
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
1.0K
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

83
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
83
Imaging Studies III: Computed Tomography01:27

Imaging Studies III: Computed Tomography

492
DefinitionComputed Tomography (CT) of the genitourinary (GU) tract is a non-invasive imaging modality that utilizes X-rays and computer processing to generate detailed cross-sectional images of the urinary system, encompassing the kidneys, ureters, bladder, and adjacent structures such as the adrenal glands.PurposeCT scans of the GU tract serve several diagnostic and therapeutic purposes, including:Diagnosis of Urinary Tract Diseases: Detects kidney stones, tumors, cysts, and congenital...
492
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

61
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
61
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

69
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
69
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

317
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
317

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role.

Archives of toxicology·2025
Same author

Erratum for: CT/MRI LI-RADS 2024 Update: Treatment Response Assessment.

Radiology·2025
Same author

Gadolinium Elimination in a Gadolinium Deposition Disease Population After a Single Exposure to Gadolinium-Based Contrast Agents.

Investigative radiology·2024
Same author

CT/MRI LI-RADS 2024 Update: Treatment Response Assessment.

Radiology·2024
Same author

Near-cure in patients with Gadolinium deposition disease undergoing intravenous DTPA chelation.

Frontiers in toxicology·2024
Same author

Abdominal Wall Needle Tract Seeding: 15 Years After a Hepatocellular Carcinoma Biopsy.

Cureus·2024

Related Experiment Video

Updated: Mar 2, 2026

An Aptamer-based Sensor for Unchelated GadoliniumIII
05:15

An Aptamer-based Sensor for Unchelated GadoliniumIII

Published on: January 9, 2017

7.8K

Gadolinium Retention and Toxicity-An Update.

Miguel Ramalho1, Joana Ramalho1, Lauren M Burke1

  • 1Department of Radiology, Hospital Garcia de Orta, Almada, Portugal; Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC; and Department of Radiology, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

Advances in Chronic Kidney Disease
|May 15, 2017
PubMed
Summary

Gadolinium-based contrast agents (GBCAs) can deposit in the brain, regardless of kidney function. A new condition, gadolinium deposition disease, presents with symptoms similar to, but less severe than, nephrogenic systemic fibrosis.

Keywords:
Gadolinium deposition diseaseGadolinium storage conditionGadolinium-based contrast agentsToxicity

More Related Videos

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
13:21

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

15.4K
Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications
11:28

Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications

Published on: April 28, 2015

10.8K

Related Experiment Videos

Last Updated: Mar 2, 2026

An Aptamer-based Sensor for Unchelated GadoliniumIII
05:15

An Aptamer-based Sensor for Unchelated GadoliniumIII

Published on: January 9, 2017

7.8K
Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
13:21

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

15.4K
Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications
11:28

Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications

Published on: April 28, 2015

10.8K

Area of Science:

  • Radiology
  • Nephrology
  • Neurology

Background:

  • Historically, gadolinium-based contrast agent (GBCA) safety focused on short-term reactions.
  • Nephrogenic systemic fibrosis (NSF) emerged as a risk in patients with renal failure exposed to specific GBCAs.
  • Emerging evidence links GBCAs to gadolinium deposition in the brain, independent of renal function or GBCA stability.

Purpose of the Study:

  • To review gadolinium toxicity, focusing on nephrogenic systemic fibrosis and the newly described gadolinium deposition disease.
  • To discuss the implications of gadolinium deposition in the brain.

Main Methods:

  • Literature review of studies on gadolinium-based contrast agents, nephrogenic systemic fibrosis, and gadolinium deposition in the brain.
  • Analysis of reported patient cases and scientific findings regarding GBCA toxicity.

Main Results:

  • Gadolinium deposition occurs in the brain in a significant number of cases, irrespective of renal function or GBCA stability.
  • Gadolinium deposition disease is a newly identified condition with symptoms that may resemble NSF but are generally less severe.
  • No definitive clinical findings are currently associated with gadolinium deposition in brain tissue.

Conclusions:

  • Gadolinium deposition in the brain is a confirmed phenomenon requiring further investigation.
  • Gadolinium deposition disease represents a potential, albeit infrequent, clinical concern related to GBCA exposure.
  • Continued research is necessary to understand the clinical significance and long-term effects of gadolinium deposition in the brain.